原发性胆囊癌是胆道系统最常见的恶性肿瘤，其发病率在我国逐年增高。由于原发性胆囊癌无特异性的临床表现，临床发现的胆囊癌多属中晚期，根治性切除率低，预后差。更好地了解胆囊癌变的分子基础，推出新的分子“靶点”化疗药物，可改善病人的预后，靶向治疗正逐渐发展成为治疗原发性胆囊癌的一种新方法，己显示出良好的应用前景。

Targeted therapy of gallbladder carcinoma        LIU Ying-bin*, WU Wen-guang, QUAN Zhi-wei. *Xinhua Hospital, Shanghai Jiaotong University，Shanghai 200092, China
Corresponding  author: LIU Ying-bin，E-mail: laoniulyb@163.com
Abstract    Primary carcinoma of the gallbladder (PCG) is the most common malignant tumor in biliary system and its morbility has been rising year by year in our country. Because there is no specific clinical manifestation, patients diagnosed finally as PCG has mostly been in intermediate or advanced stage, thus losing the chance of radical resection of gallbladder carcinoma and having a poor prognosis. Improved understanding of the molecular carcinogenesis of adenocarcinomas of the gallbladder, coupled with the availability of novel molecularly targeted chemotherapeutic agents, may improve outcome for patients. Targeted therapy has gradually developed to become a new therapy and displays favourable prospect of application.